Clinical trial
Effects of Arzoxifene on Bone Mass and the Uterus
NCT00085956 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00085956 |
|---|---|
| Title | Effects of Arzoxifene on Bone Mass and the Uterus |
| Official title | Effects of Arzoxifene on Bone Mineral Density and Endometrial Histology in Postmenopausal Women. |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Postmenopausal Bone Loss |
| Intervention type | Drug |
| Interventions | Arzoxifene, Placebo |
| Enrollment | 300 |
| Start date | Apr 1, 2004 |
| Completion | Feb 1, 2007 |
| First posted | Jun 22, 2004 |
| Last update posted | Mar 9, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: